Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.
Also called NCT01201837
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 507 participants
- Sponsor
- Cerenis Therapeutics, SA
- Registry
-
NCT01201837
-
- Other papers using this trial's data
- Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, France, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01201837. Randomized; quadruple masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2012-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
- Acronym
- CHI SQUARE
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- CER-001
- Lead sponsor
- Cerenis Therapeutics, SA
Record details
- Record id
cardio:ct-nct01201837- Content hash
1cae2348ec7ad01db512899f97b658682c77941f2bf12561e292f75b8a318932